Transforming growth factor-beta 1 levels are elevated in the striatum and in ventricular cerebrospinal fluid in Parkinson's disease.
Transforming growth factor (TGF)-beta 1 content was measured for the first time in the brain (caudate nucleus, putamen, and cerebral cortex) and in ventricular cerebrospinal fluid (VCSF) from control and parkinsonian patients by a sandwich enzyme immunoassay. The concentrations of TGF-beta 1 were significantly higher in the dopaminergic striatal regions in parkinsonian patients than those in controls, but were not significantly different in the cerebral cortex between parkinsonian and control patients. Furthermore, the concentrations of TGF-beta 1 in VCSF were significantly higher in parkinsonian patients than those in non-parkinsonian control patients. Since TGF-beta 1 has potent regulatory activity on cell growth, these results suggest that TGF-beta 1 may have some significant modulatory role in the process of neurodegeneration in Parkinson's disease.
D000368:Aged; D000369:Aged, 80 and over; D002552:Cerebral Ventricles / Q000378:metabolism; D005260:Female; D006131:Growth Inhibitors / Q000378:metabolism; D006133:Growth Substances / Q000378:metabolism; D006801:Humans; D008297:Male; D008875:Middle Aged; D017072:Neostriatum / Q000378:metabolism*; D010300:Parkinson Disease / Q000134:cerebrospinal fluid / Q000378:metabolism*; D013378:Substantia Nigra / Q000378:metabolism; D016212:Transforming Growth Factor beta / Q000134:cerebrospinal fluid / Q000378:metabolism*
D006131:Growth Inhibitors; D006133:Growth Substances; D016212:Transforming Growth Factor beta